Delta-8, delta-9 and THC, explained

Cannabis produces more than a hundred cannabinoids. Delta-9-tetrahydrocannabinol is the main intoxicating one and the compound people mean when they say THC without qualification. CBD, cannabidiol, is the main non-intoxicating one.

Delta-8-THC is an isomer of delta-9: identical atoms, differing in the position of one double bond in the molecular ring. It occurs naturally in cannabis only in trace amounts, far too little to extract economically. Essentially all commercial delta-8 is produced by chemically converting CBD in a lab, using acid catalysts.

Delta-8 is genuinely intoxicating. It is commonly reported as producing a milder effect than delta-9, but the comparison rests largely on user report rather than controlled study, and dose matters more than isomer — a high-dose delta-8 product is not mild.

THCA is tetrahydrocannabinolic acid, the non-intoxicating precursor that cannabis actually produces. Heating it converts it to delta-9 THC, which is what happens when it is smoked or vaped. 'THCA flower' was sold nationally on the argument that it tested under the delta-9 limit in its raw state, despite becoming delta-9 the moment it was used as intended.

Delta-10, HHC, THC-O, THCP and a growing list of others follow the same commercial logic: a cannabinoid the 2018 statute did not name, synthesised or concentrated from hemp, sold into states without a legal cannabis market.

The Agriculture Improvement Act of 2018 — the Farm Bill — removed hemp from the Controlled Substances Act and defined it as Cannabis sativa containing no more than 0.3 percent delta-9 THC on a dry weight basis.

Every part of that definition was doing work that its drafters appear not to have anticipated. It capped delta-9 specifically, saying nothing about other isomers. It measured on a dry weight basis, a metric that makes sense for plant material and very little sense for a gummy or a beverage, where a product can hold a large absolute dose while remaining a tiny percentage of its total weight. And it did not distinguish cannabinoids the plant produces from cannabinoids made in a lab from plant-derived inputs.

The result was an industry built entirely inside those three gaps. Delta-8 exploited the isomer gap. High-dose delta-9 edibles and seltzers exploited the dry weight gap, staying under 0.3 percent by weight while delivering a full recreational dose. THCA flower exploited the fact that the test is applied before the heat that creates the delta-9.

The DEA's position over this period was that synthetically derived tetrahydrocannabinols remain controlled substances regardless of source, which cut directly against the industry's reading. Federal courts did not resolve the conflict cleanly, and a Ninth Circuit decision in particular read the statutory text as covering delta-8. The practical outcome was years of genuine legal ambiguity in which the products were sold openly and enforcement was rare.

Meanwhile states did what states do in a federal vacuum: dozens legislated, in every direction. Some banned intoxicating hemp cannabinoids outright, some folded them into their regulated cannabis market, some imposed potency caps and age limits, and some did nothing at all.

The Continuing Appropriations Act, 2026 was signed on 12 November 2025. Its hemp provisions take effect 365 days later, on 12 November 2026.

It rewrites the federal definition of hemp in three ways, each of which independently removes most current products from the category.

First, the limit is no longer 0.3 percent delta-9 by dry weight. Final consumer products are limited to 0.4 milligrams of total tetrahydrocannabinols per container, and 'total THC' expressly includes delta-8, delta-10, other isomers and THCA. Intermediate hemp-derived cannabinoid products face a 0.3 percent total THC ceiling. A per-container milligram cap does what a dry-weight percentage could not: it makes the absolute dose the test, so a heavy gummy no longer dilutes its way into compliance.

Second, cannabinoids that are synthesized or manufactured outside the plant are excluded from the definition of hemp entirely, regardless of concentration. Since essentially all commercial delta-8 is lab-converted from CBD, this alone removes it.

Third, the definition excludes cannabinoids not capable of being naturally produced by Cannabis sativa, and cannabinoids with effects similar to THC — or marketed as having similar effects — as determined by the Department of Health and Human Services. That last clause is deliberately anticipatory: it is written to catch the next novel cannabinoid rather than requiring a new statute each time one appears.

Agencies were given 90 days to publish lists of naturally occurring cannabinoids and of those with THC-like effects. Those lists are the operative detail and should be checked directly, because they determine which specific compounds fall inside and outside the new definition.

The law preserves state authority. States retain broad power to regulate and limit hemp production and sale within their borders, so a state may be stricter than the federal floor but cannot authorize what federal law now excludes.

One widely noted consequence: the 0.4 mg per container cap is low enough that industry analysts estimate it captures the large majority of CBD products currently on sale, not only intoxicating ones, because full-spectrum CBD contains trace THC that can exceed 0.4 mg across a whole bottle.

Delta-8 products are intoxicating and impairing. Driving under their influence is impaired driving, and is prosecuted as such regardless of the product's federal status.

The FDA has warned specifically about delta-8 and has documented adverse event reports including vomiting, hallucinations, loss of consciousness and hospitalizations. Pediatric exposures via edibles packaged to resemble mainstream candy and snack brands are a recurring and serious problem, and poison center calls involving delta-8 rose substantially over the period the market grew.

The manufacturing process is the underexamined risk. Converting CBD to delta-8 uses acids and solvents and produces reaction byproducts alongside the target molecule, including isomers and compounds that are not well characterized. Independent testing has repeatedly found products whose actual cannabinoid content differs materially from the label, contains delta-9 above the legal limit, or contains residual solvents and heavy metals. There is no federal manufacturing standard for these products.

Certificates of analysis accompany many products and are of uneven value. Some are genuine, some are from labs of unknown quality, some belong to a different batch than the product they are attached to, and some are simply fabricated. A certificate is a document, not an assurance.

Vaped THC products carry the additional lesson of EVALI. The 2019–2020 outbreak that caused 2,807 hospitalizations and 68 deaths was traced to vitamin E acetate used as a thickening diluent in illicit THC cartridges. That is the clearest available demonstration of what an unregulated additive in an inhaled cannabis product can do.

Delta-8 will produce a positive result on a standard drug test. Immunoassay tests detect THC metabolites and do not distinguish isomers, so 'it was legal hemp' is not a defense that a test result can support.

The commercial effect is broad. An industry estimated at $28 billion loses the definition it was built on, and the intoxicating segment faces federal elimination unless Congress passes corrective legislation before the deadline — which has been sought and is not assured.

State-legal cannabis is unaffected. The change concerns the federal hemp definition, not state cannabis programs, which continue to operate as they did, under their existing conflict with federal law.

Products likely to disappear from general retail: delta-8 and delta-10 in all formats, HHC, THC-O, THCP and comparable novel cannabinoids, THCA flower, high-dose delta-9 edibles and beverages sold outside licensed cannabis channels, and a substantial share of full-spectrum CBD exceeding 0.4 mg total THC per container.

Products likely to remain: CBD isolate and broad-spectrum CBD within the new limit, hemp fiber, hemp seed and hemp seed oil, and cannabis products sold through state-licensed cannabis programs where those exist.

For anyone currently buying these products, the practical point is that this is a known dated change, not a rumour. The compounds do not become more or less safe on 12 November 2026 — but their legal status, their availability and, in the interim, the incentives of the people selling off remaining stock all change.

Check the agency lists and any corrective legislation before relying on any of this. This is the single fastest-moving area covered anywhere on this site.